Exchange: OTC·Updated 03:47 PM EST

MDNAF News

News
all
press releases
Medicenna Therapeutics (MDNAF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
Medicenna Therapeutics (MDNAF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks

Advertisement|Remove ads.